key: cord-0319546-wnlroru3
authors: Shemuelian, Z.; Warszawer, Y.; Or, O.; Arbel-Alon, S.; Giladi, H.; Avgil Tsadok, M.; Cohen, R.; Shefer, G.; Maruotti, A.; Jona Lasinio, G.; Galun, E.
title: BNT162b2 post-exposure-prophylaxis against COVID-19
date: 2022-01-08
journal: nan
DOI: 10.1101/2022.01.07.22268869
sha: 68f24eb601e7cabe0be6e49bbb8bf4b1a31ad641
doc_id: 319546
cord_uid: wnlroru3

Background: During the COVID-19 pandemic, post-exposure-prophylaxis is not a practice. Following exposure, only patient isolation is imposed. Moreover, no therapeutic prevention approach is applied. We asked whether evidence exists for reduced mortality rate following post-exposure-prophylaxis. Methods: To estimate the effectiveness of post-exposure-prophylaxis, we obtained data from the Israeli Ministry of Health (MoH) registry. The study population consisted of Israeli residents aged 12 years and older, identified for the first time as PCR-positive for SARS-CoV-2, between December 20th, 2020 (the beginning of the vaccination campaign) and October 7th, 2021. We compared 'recently injected' patients - that proved PCR-positive on the same day or on one of the five consecutive days after first vaccination (representing an unintended post-exposure-prophylaxis), to unvaccinated control group. Results: Among Israeli residents identified PCR-positive for SARS-CoV-2, 11,690 were found positive on the day they received their first vaccine injection (BNT162b2) or on one of the 5 days thereafter. In patients over 65 years, 143 deaths occurred among 1413 recently injected (10.12%) compared to 280 deaths among the 1413 unvaccinated (19.82%), odd ratio (OR) 0.46 (95% confidence interval (CI), 0.36 to 0.57; P<0.001). The most significant reduction in the death toll was observed among the 55 to 64 age group, with 8 deaths occurring among the 1322 recently injected (0.61%) compared to 43 deaths among the 1322 unvaccinated control (3.25%), OR 0.18 (95% CI, 0.07 to 0.39; P<0.001). Conclusion: Post-exposure-prophylaxis is effective against death in COVID-19 infection. Israeli MoH Registry Number: HMO-0372-20

SARS-CoV-2 vaccination has proved effective in preventing clinical COVID-19 infection (1) . Numerous drugs had shown some benefit to patients with COVID-19. These include the following compounds: Remdesivir (2) , Paxlovid which received an emergency use in PCRpositive patients (3) , the anti-inflammatory drugs Dexamethasone (4) and anti-IL6 receptor (5) and some compounds in clinical development such as Molnupiravir (6) . However, the therapeutic benefit from most of these treatments is still suboptimal so additional therapeutic approaches are needed to reduce the loss of human lives. One potential clinical approach is post exposure vaccination prophylaxis. Post exposure vaccination prophylaxis is an old approach used to attenuate severe infections by busting an efficient immune response. This is adopted following bacterial infections in the case of tetanus, but is more common following exposure to viral infections. Although the post exposure approach is many times specific to the viral infection context, as for hepatitis B virus (7) or after a bite from a rabies infected dog, the concept is generally the same (8) . Thus, active vaccination with the attenuated/killed pathogen or viral associated protein is a very effective mean to attenuate and almost eliminate any infection related symptoms. This approach is now also suggested for Ebola virus infection (9) . In accordance, it was recently shown that the overall neutralizing potency of plasma is greater following vaccination compared to natural infection with SARS-CoV-2 (10) . In the case of vaccinating a patient with COVID-19 respiratory illness, it is expected that upon vaccination an efficient immune response against SARS-CoV-2 will develop in a remote site from the pneumonitis developed in the lung, possibly preventing respiratory deterioration. Post exposure vaccination prophylaxis is particular relevant in light of the waning immunity against COVID-19 after BNT162b2 vaccination (11) (12) (13) (14) . We wish to determine in the real world, whether vaccinating patients who were already infected by SARS-CoV-2 will benefit from post-exposure prophylaxis vaccination. This could be in particular relevant as a measure undertaken together with isolation strategies following exposure. We performed this investigation by a data mining study on an available national database.

In this observational study, we analyzed nationwide surveillance data obtained from the Israeli Ministry of Health (MoH) registry to assess the effectiveness of the BNT162b2 vaccine as post exposure prophylaxis approach against the clinical outcomes of SARS-CoV-2 infection. Our study population consisted of Israeli residents aged 12 years and older, identified for the first time as PCR-positive for SARS-CoV-2, between December 20 th , 2020 (the beginning of the vaccination campaign) and October 7 th , 2021, and did not include patients that were found PCR-positive 6 days or later after they received the first vaccine injection (Fig. S1 ). The data on each patient included: age, gender, first positive PCR date, first vaccination date, hospitalization dates (arrival and discharged) and date of death. We compared two groups: Group1) the "recently injected" test group -patients proved PCR-positive on the same day or on one of the five consecutive days after receiving their first vaccine injection. This group was chosen because it practically represents an unintended post exposure prophylaxis treatment. Group2) The control unvaccinated group. To establish this control group, we matched the "recently injected" group to the unvaccinated controls using the following variables: gender, age and date of the first positive PCR, variables associated with the severity of COVID-19.

Anonymized data, without any personal identifiers, were used in this analysis. This study was approved by the Hadassah Hebrew University Hospital institutional review board (IRB approval number HMO-0372-20). The study was exempt from the requirement for informed consent.

The primary outcome was COVID-19 related death (reported to the Israeli MOH) within 60 days after the first positive PCR date. Secondary outcomes were: 1) Hospitalization for COVID-19 (hospitalization in COVID-19 designated department, at the time interval between 2 days before PCR-positive and 21 days thereafter) Fig. S2 ; 2) Hospitalization duration.

For estimating the treatment effect in this observational study and to produce inferences that are more robust and less sensitive to modelling assumptions, we perform propensity score matching (15) so that we can further control for measured confounding variables, namely the gender, age and the date of the first positive PCR. One by one, each treated unit is paired with an available control unit that has the closest propensity score to it, the so called 1:1 nearest neighbor matching. Any remaining control units are left unmatched and excluded from further analysis. The goal of matching is to produce covariate balance, that is, for the distributions of covariates in the two groups to be approximately equal to each other, as they would be in a successful randomized experiment. The importance of covariate balance is that it allows for increased robustness to the choice of model used to estimate the treatment effect; in perfectly balanced samples, a simple difference in means can be a valid treatment effect estimate (loveplot: https://ngreifer.github.io/cobalt/reference/love.plot.html). Survival curves for the recently injected and unvaccinated groups were estimated using the Kaplan-Meier estimator (16, 17) analyzing death, and hospitalization probability. Fisher exact test was used to assess the association between vaccination status and the main outcomes distinguishing by age group and gender. For significant association at Fisher exact test, we calculated odds ratio (OR) and 95% confidence interval (CI). A negative binomial generalized linear model was estimated to evaluate the relation between duration of hospitalization and all interactions among age groups, vaccination status and gender. Count data may be distributed as Negative Binomial if the rate, at which events occur, is heterogeneous, and consequently the counts are characterized by overdispersion compared to the Poisson (as typically happens in our length of hospitalization data). The Poisson distribution is nested within the Negative Binomial, in the sense that if no overdispersion/heterogeneity is present, the Negative Binomial distribution converges to the Poisson distribution.

Our study population included 271,710 Israeli residents that were identified PCR-positive for SARS-CoV-2 during the period between December 20 th , 2020 and October 7 th , 2021, (Fig.1 ). Among them, 11,690 were found positive on the same day they received their first vaccine injection (BNT162b2, Pfizer, USA) or on one of the 5 days thereafter i.e., "recently injected" group. We matched the recently injected group to unvaccinated controls according to the following variables: age, age group, gender and date (Fig.1) . The characteristics of the matched unvaccinated control and the recently injected group are shown in Table 1 . Notably, there are no differences in demographic characteristics between the two groups (Fig. S3) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 8, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 8, 2022. ; https://doi.org/10.1101/2022.01.07.22268869 doi: medRxiv preprint

Mortality up to 60 days from first positive PCR, among infected people, 55 years of age and beyond, in all age groups and gender, was significantly lower in the recently injected group compared to the unvaccinated control group (Table 2 ). In the combined group of patients over 65 years and beyond, male and female, 143 deaths occurred among 1413 recently injected (10.12%) compared to 280 deaths among the 1413 unvaccinated (19.82%), odd ratio (OR) 0.46 (95% confidence interval (CI), 0.36 to 0.57; P<0.001) Fig. 2 . Importantly, the most significant reduction in the death toll was observed among the combined 55 to 64 age group, with 8 deaths occurring among the 1322 recently injected (0.61%) compared to 43 deaths among the 1322 unvaccinated control (3.25%), OR 0.18 (95% CI, 0.07 to 0.39; P<0.001). Under the age of 55, we observed a very low death toll overall, with a borderline statistically significant difference between the groups. When combining all the patients aged 12-55 in both genders 10 deaths occurred among the 8955 recently injected group (0.11%) compared to 22 deaths among the 8955 unvaccinated control group (0.25%), OR 0.45 95% CI, 0.19 to 0.99; P=0.049). Analysis of each group separately did not yield significant difference, possibly due to the low death events in these age groups (Fig. S4 -Fig S9) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 8, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 8, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 8, 2022. ; https://doi.org/10.1101/2022.01.07.22268869 doi: medRxiv preprint P< 0.001). A similar reduced hospitalization rate was seen in the 55-64 combined group, 81/1322 (6.13%) versus 115/1322 (8.70%), respectively (OR 0.69 95% CI, 0.50 to 0.93; P=0.014) (Fig 2, Table 3 and Fig S10-Fig. S15 ). Regarding the analysis on the length of hospitalization, we didn't find any statistically significant effect of vaccination status. From our analysis, only age and gender play a role in the estimation of the hospitalization duration, with males and older age groups confirmed to increase the hospitalization length. No other interactions were significant.

The death toll from COVID-19 is rising, and numerous strategies are essential to reduce this mortality rate world-wide. In this report we show that the BNT162b2 vaccine could also be applied to patients as a post exposure prophylaxis manner, significantly reducing the death burden at the high-risk groups of age patients by 50%. We propose that this approach could be used with a significant positive impact on survival following SARS-CoV-2 exposure as well as upon hospitalization. There are numerous potential benefits in using this post-exposure prophylaxis approach. In many countries, once an individual is identified as positive by PCR for SARS-CoV-2, an epidemiological investigation is performed to identify those exposed to . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 8, 2022. ; this COIVID-19 patient. These identified individuals are then isolated without any preventive treatment. We propose that as in other post exposure prophylaxis infectious events, the exposed individuals should be vaccinated to prevent severe disease culminating in hospitalization and in some cases leading to death. In many countries, the availability of vaccines is low. One question remains as to whom should the vaccine be provided. It is accepted in many societies that prioritization is to provide the vaccine to the aged, immunosuppressed patients and the medical staff. It could be also beneficial to include in this selected group of individuals, vaccination to SARS-CoV-2-exposed patients. This post-exposure prophylaxis could have an advantage of halting, or at least attenuating, the spread of the virus, possibly by reducing its titer in the respiratory track of exposed individuals. This approach is substantiated by the fact that infected patients are spreading the virus prior to the occurrence of symptoms (18) .

Based on our findings, we propose that additional approaches should be investigated to potentially expand the usage of post exposure prophylaxis to reduce COVID-19 morbidity. Patients who develop severe respiratory symptoms, including low saturated oxygen (<93%), increased respiratory rate (>18/min) and pulmonary infiltrates on chest x-ray, could potentially benefit from a vaccination which would overcome the SARS-CoV-2 infection-related deterioration to pneumonitis and adult respiratory distress syndrome. Recently, an investigation that compared adult and children immune response to SARS-CoV-2 had shown that activation of the immune response in children results in an attenuation of infection (19). Stimulating the interferon response by vaccination could improve the immune reaction, simulating the children natural history of SARS-CoV-2 infection. It is well accepted that one important determinant in the outcome of COVID-19 infection is the genetic alterations in interferon pathway genes (20) . Post-exposure prophylaxis could skew the immune response to enhance the interferon signaling pathways (21) .

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Remdesivir for the Treatment of Covid-19 -Final Report

Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports

Dexamethasone in Hospitalized Patients with Covid-19

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

Molnupiravir: coding for catastrophe

CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management

Rabies post-exposure prophylaxis: A systematic review on abridged vaccination schedules and the effect of changing administration routes during a single course

Ebola virus disease: an update on post-exposure prophylaxis

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Waning Immunity after the BNT162b2 Vaccine in Israel

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Nonparametric Preprocessing for Parametric Causal Inference

Nonparametric estimation from incomplete observations

Modeling Survival Data: Extending the Cox Model

SARS-CoV-2 Transmission From People Without COVID-19 Symptoms

The emergence, genomic diversity and global spread of SARS-CoV-2

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

The authors would like to thank Mrs. Nofar Avni, BI Developer from the IT Unit and Mrs. Olga Litinetsky (Slutsky) Head of Data Research Unit, Research Fund of the Hadassah

The research of Antonello Maruotti and Giovanna Jona-Lasinio has been partially supported by the Ministero dell'Istruzione, dell'Università e della Ricerca, project number FISR2020IP_00156 "Modelli statistici inferenziali per governare l'epidemia" (SMIGE).

The authors declare no conflict of interest.